25 year spotlight: Dr Jennifer Shannon


The AGITG is an exceptional team of medical researchers, clinicians, consumers and support staff with whom I am privileged to work. I have been inspired by every member of this team throughout my years of association. The strength of the AGITG lies in the dedication of its members from whom I have learnt so much. — Dr Jennifer Shannon

Medical oncologist Dr Jennifer Shannon has been a member of the AGITG since June 2004 and served on the Scientific Advisory Committee (SAC) since February 2009.

Dr Shannon trained in Sydney at Royal North Shore, and then Westmead Hospitals. Completing her PhD in 1999, she has been the Head of the Department of Medical Oncology at Nepean Hospital since 2000.  In addition to this Dr Shannon is the Deputy Director of Sydney West Cancer Network and was involved in establishing the clinical trial service at the Nepean Cancer Care Centre.

Since becoming a member, Dr Shannon has published over 13 journal articles and conference presentations in relation to AGITG research. Well established in clinical trial research, Dr Shannon has worked as Principal Investigator on many AGITG trials, including exploration of new treatment for bowel cancer, pancreatic cancer and biliary tract cancer (BTC). She was study chair for the recent TACTIC trial, examining the role of panitumumab with chemotherapy in advanced bile duct and gallbladder cancers.

Dr Shannon is passionate about finding better treatments for biliary tract cancer, an uncommon yet devastating disease. In 2015, Dr Shannon was awarded close to $500 000 funding from Cancer Australia’s Priority-driven collaborative cancer research scheme for the ACTICCA-1 study. Looking to open for recruitment in the second quarter of this year, ACTICCA-1 aims to find out for the first time whether combination chemotherapy given after surgery can delay or prevent BTC cancer from returning.

“We really have limited treatment options for advanced or inoperable biliary tract cancer. We need more clinical research to prolong survival and quality of life. It is vital to find better ways to treat this cancer.” Says Dr Shannon

Donate Now